Sensitive Quantitation of Glucagon-Like Peptide-1 (GLP-1) Analog Semaglutide from Plasma

Significance of the Topic

The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, particularly semaglutide, has transformed treatment strategies for obesity and type 2 diabetes. Bioanalytical assays with high sensitivity and specificity are vital to characterize pharmacokinetics and toxicokinetics, accelerating drug discovery and regulatory approval pathways.

Objectives and Study Overview

This study aimed to develop and validate an automated LC/MS workflow for quantifying semaglutide in human plasma without antibody reagents. Key goals included enhancing assay sensitivity, expanding dynamic range, and reducing manual sample preparation steps to support high-throughput analysis in preclinical and clinical research.

Methodology

The workflow comprised two main stages:

• Sample Cleanup
  • Protein precipitation using acetonitrile:methanol (1:1) on 100 µL plasma spiked with semaglutide and tirzepatide internal standard.
  • Automated solid-phase extraction on Agilent AssayMAP RP-S cartridges for further purification.
• LC/MS Analysis
  • Agilent 1290 Infinity II bio UHPLC with AdvanceBio Peptide Mapping column (2.1×150 mm, 2.7 µm) at 80 °C.
  • Gradient elution from 30% to 95% acetonitrile with 0.1% formic acid at 0.4 mL/min.
  • Agilent 6495D triple quadrupole mass spectrometer in positive electrospray mode.
  • MRM transitions optimized: semaglutide [M+4H]4+ (m/z 1029.4 → 1238.1 quantifier, 1029.4 → 136.1 qualifier), tirzepatide (1204.4 → 396.2).

Instrumentation

• Agilent AssayMAP Bravo protein sample prep platform
• Agilent 1290 Infinity II bio LC system (pump, multisampler, column compartment)
• Agilent 6495D triple quadrupole LC/MS with Jet Stream ESI source
• Agilent AdvanceBio Peptide Mapping column

Key Results and Discussion

Method optimization focused on solvent composition, buffer conditions, and SPE parameters:

• ACN:MeOH (1:1) achieved highest peptide recovery in precipitation.
• Pure water as loading buffer, 10 mM ammonium formate pH 10 with 10% ACN for washing, and 5% formic acid in 80% ACN for elution maximized cleanliness.
• Automated AssayMAP cleanup enhanced sensitivity fivefold compared to conventional precipitation.

Quantitative performance:

• Lower limit of quantification (LLOQ): 0.2 ng/mL with signal-to-noise > 10.
• Linear dynamic range: 0.2–1000 ng/mL (R2 = 0.9946, weighted 1/x2).
• Intra- and interday precision and accuracy within ±15% across QC levels (LLOQ, low, mid, high).

Benefits and Practical Applications

This automated platform offers:

• Ultra-sensitive detection of GLP-1 analogs without immunoassays.
• High specificity via MRM transitions and peptide mapping column.
• Reduced hands-on time and improved reproducibility.
• Applicability to multiple GLP-1 therapeutics in drug development workflows.

Future Trends and Applications

Advancements may include multiplexed quantitation of diverse peptide therapeutics, integration with microflow LC for sample economy, and application to endogenous peptide biomarkers. Further miniaturization and on-line automation will support personalized dosing studies and translational research.

Conclusion

The presented automated LC/MS assay delivers robust, high-sensitivity quantitation of semaglutide in human plasma. By combining Agilent AssayMAP cleanup, 1290 Infinity II LC, and 6495D TQMS, the method achieves a 0.2 ng/mL LLOQ, wide dynamic range, and regulatory-grade precision. This universal approach streamlines peptide bioanalysis across discovery and clinical phases.

References

1. Ozempic – semaglutide injection, solution. DailyMed. 5 June 2021.
2. Rybelsus – oral semaglutide tablet. DailyMed. 5 June 2021.
3. Wegovy – semaglutide injection, solution. 14 Dec. 2021.